Physician profile
Barbara Greenling
NPI 1467480715
$15,074.70
in general payments reported to CMS, 2019-2025
47 companies · $2,876 in 2025
The $2,876 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,958 · 2022: $2,415 · 2023: $4,712 · 2024: $3,113 · 2025: $2,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,400 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Travel and Lodging: $1,842 · Education: $60.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,399.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Travel and Lodging | $1,842.08 |
| Education | $60.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $4,270.46 | 2021-2023 | Dexcom G7 Gss (161) |
| Medtronic, INC. | $3,087.22 | 2021-2025 | Minimed 780g, Closurefast, Ligasure |
| Astrazeneca Pharmaceuticals LP | $1,379.77 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,276.61 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,063.49 | 2021-2025 | |
| Lilly USA, LLC | $436.24 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $335.63 | 2021-2025 | Repatha, Otezla, Repatha |
| Insulet Corporation | $292.47 | 2024-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $249.69 | 2024-2025 | |
| Abbott Laboratories | $228.64 | 2022-2025 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $220.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.15 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $198.35 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $159.22 | 2024 | Voquezna |
| Cequr Corporation | $152.10 | 2024 | Cequr Simplicity |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $123.44 | 2022 | |
| Xeris Pharmaceuticals, INC. | $111.88 | 2024-2025 | Gvoke Hypopen |
| Koya Medical, INC. | $108.49 | 2025 | Koya Medical, Dayspring |
| Exact Sciences Corporation | $104.28 | 2023-2025 | Cologuard Collection Kit |
| Ascensia Diabetes Care US INC. | $91.10 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.01 | 2023-2025 | Xifaxan |
| Corcept Therapeutics | $72.11 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $66.44 | 2021-2024 | |
| Pfizer INC. | $65.67 | 2021-2025 | |
| Lundbeck LLC | $65.56 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $64.38 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $62.22 | 2025 | Rexulti |
| Sequel Med Tech, LLC | $47.80 | 2025 | Twiist |
| Mannkind Corporation | $42.90 | 2021 | |
| Beta Bionics, INC. | $41.63 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Solventum Corporation | $39.15 | 2025 | V.A.C. Veraflo, Prevena, V.A.C.Ulta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.38 | 2024 | Caplyta |
| Smith+Nephew, INC. | $29.58 | 2024-2025 | Collagenase Santyl |
| Davol INC. | $29.15 | 2025 | Arista |
| Merck Sharp & Dohme LLC | $28.26 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.16 | 2021-2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $23.96 | 2021 | |
| Phadia US INC. | $20.12 | 2025 | Immunocap |
| Ardelyx, INC. | $18.97 | 2025 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $18.72 | 2025 | Xhance, Nuzyra |
| Janssen Pharmaceuticals, INC | $16.58 | 2021 | |
| Sanofi Pasteur INC. | $13.99 | 2021 | |
| Nabriva Therapeutics, Plc | $13.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2021 | |
| Radius Health, INC. | $13.31 | 2021 | |
| Glaxosmithkline, LLC. | $13.25 | 2024 | Trelegy Ellipta |
| Ibsa Pharma INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Greenling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.